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Abstract. Histone deacetylases (HDACs) are enzymes 
involved in transcriptional repression. We aimed to examine 
the significance of HDAC1 and HDAC2 gene expression in 
the prediction of recurrence and survival in 156 patients 
with hepatocellular carcinoma (HCC) among a South East 
Asian population who underwent curative surgical resec-
tion in Singapore. We found that HDAC1 and HDAC2 were 
upregulated in the majority of HCC tissues. The presence 
of HDAC1 in tumor tissues was correlated with poor tumor 
differentiation. Notably, HDAC1 expression in adjacent non-
tumor hepatic tissues was correlated with the presence of 
satellite nodules and multiple lesions, suggesting that HDAC1 
upregulation within the field of HCC may contribute to tumor 
spread. Using competing risk regression analysis, we found 
that increased cancer-specific mortality was significantly asso-
ciated with HDAC2 expression. Mortality was also increased 
with high HDAC1 expression. In the liver cancer cell lines, 
HEP3B, HEPG2, PLC5, and a colorectal cancer cell line, 
HCT116, the combined knockdown of HDAC1 and HDAC2 
increased cell death and reduced cell proliferation as well as 
colony formation. In contrast, knockdown of either HDAC1 or 
HDAC2 alone had minimal effects on cell death and prolif-
eration. Taken together, our study suggests that both HDAC1 
and HDAC2 exert pro-survival effects in HCC cells, and the 
combination of isoform-specific HDAC inhibitors against both 
HDACs may be effective in targeting HCC to reduce mortality.
Introduction
Histone deacetylases (HDACs) are enzymes involved in tran-
scriptional repression mainly through removal of acetyl groups 
from the positively charged histone tails and allowing histones 
to wrap the DNA tightly. In addition to deacetylating histones, 
they also deacetylate non-histone proteins, resulting in protein 
degradation via the ubiquitin-proteasome pathway (1). HDACs 
exist as components in multiprotein complexes with transcrip-
tional co-repressors, such as mSin3, N-CoR and SMRT (2). 
These complexes target specific genomic regions by inter-
acting with DNA binding factors such as transcription factors, 
nuclear receptors, methyl-binding proteins, DNA methyl 
transferases and histone methyltransferases.
In mammals, there are 18 known HDAC homologs, subdi-
vided into classes I, IIa, IIb, III and IV (3). HDAC1 was the 
first identified mammalian HDAC and is considered the proto-
type of the HDAC family. It belongs to class I of HDACs and 
shares 83% amino acid identity with another class I member, 
HDAC1 and HDAC2 independently predict mortality in 
hepatocellular carcinoma by a competing risk regression model 
in a Southeast Asian population
SER YENG LER1*,  CAROL HO WING LEuNG2*,  LAY WAI KHIN3,4,  GuO-DONG Lu5, 
MANuEL SALTO-TELLEz6-8,  MIKAEL HARTMAN4,10,11,  PHILIP TSAu CHOONG IAu4, 
CELESTIAL T. YAP1,9  and  SHING CHuAN HOOI1
1Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore; 2School of Chemical and 
Life Sciences, Singapore Polytechnic; 3Investigational Medicine Unit, Dean's Office and 4Department of Surgery, 
Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, 
Republic of Singapore; 5School of Public Health, Guangxi Medical University, Nanning, Guangxi, P.R. China; 
6Cancer Science Institute of Singapore, National University of Singapore, Singapore, Republic of Singapore; 
7Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK; 8Department of Pathology, 
Yong Loo Lin School of Medicine, National University of Singapore; 9National University Cancer Institute; 
10Saw Swee Hock School of Public Health, National University of Singapore and National University Health System,  
Singapore, Republic of Singapore; 11Department of Medical Epidemiology and Biostatistics, 
Karolinska Institute, Stockholm, Sweden
Received June 24, 2015;  Accepted July 7, 2015
DOI: 10.3892/or.2015.4263
Correspondence to: Professor Celestial T. Yap or Professor Shing 
Chuan Hooi, Department of Physiology, Yong Loo Lin School of 
Medicine, National University of Singapore, Block MD9, 2 Medical 
Drive, Singapore 117597, Republic of Singapore
E-mail: phsyapc@nus.edu.sg
E-mail: shing_chuan_hooi@nuhs.edu.sg
*Contributed equally
Key words: hepatocellular carcinoma, mortality, Southeast Asian 
population, histone deacetylases
LER et al:  HDAC1 AND HDAC2 INDEPENDENTLY PREDICT MORTALITY IN HEPATOCELLuLAR CARCINOMA 2239
HDAC2 (4). Both HDAC1 and HDAC2 have almost identical 
genomic organization and this indicates that they have arisen 
from relatively recent gene duplication and probably share 
similar biological functions. They are ubiquitously expressed 
in many tissues and since they lack nuclear export signals, 
they are found exclusively in the nucleus (5). Despite having 
some overlapping biological functions, HDAC1 and HDAC2 
also have distinct and even opposing biological functions. 
For example, the deletion of HDAC1 alone is lethal in mouse 
embryos (6). There is also evidence for distinct functions of 
HDACs in cancer cells. HDAC2, but not HDAC1, can inhibit 
proliferation and induce senescence in MCF7 breast cancer 
cells (7). In addition, cellular responses to growth factors 
appear to be specific to different HDACs - silencing of HDAC1 
suppresses transforming growth factor (TGF) β1-induced 
apoptosis while silencing of HDAC2 increases spontaneous 
apoptosis and enhances TGF β1-induced apoptosis in AML12 
murine hepatocytes due to opposing effects on extracellular-
regulated kinase (ERK)1/2 (8).
Recent studies have shown elevated expression of class I 
HDACs in solid human tumors (9). HDAC1 and HDAC2 phys-
ically associate with an N-terminally truncated form of p63 
(ΔNp63α) to repress the transcription of pro-apoptotic genes 
in squamous cell carcinoma (10). In this study, we demonstrate 
that HDAC1 and HDAC2 are upregulated in hepatocellular 
carcinoma (HCC) tissues compared to matched adjacent 
non-tumor controls. This is consistent with previous studies 
that show upregulation of HDAC1 and HDAC2 in hepatocel-
lular cancer (11) and other cancers (12-14).
HCC is the most common form of liver cancer, accounting 
for 85 to 90% of all primary liver cancers (15) and liver cancer 
is the fifth most common cancer worldwide, with an alarming 
748,300 new cases and 695,900 cancer deaths in 2008 (16). 
Current treatment for HCC includes surgical resection of the 
tumor, liver transplantation, and chemotherapy, but each has 
its own problems and limitations (17-20). The use of HDAC 
inhibitors to target solid tumors such as HCC is still at an early 
stage of development. HDAC inhibitors are thought to func-
tion by reversing the aberrant epigenetic states of cancer cells. 
Although the effects of pan-HDAC inhibitors have been widely 
studied, not much is known of the differing roles of the various 
HDAC homologs in cancer. In this study, we aimed to evaluate 
the prognostic significance of HDAC1 and HDAC2 gene 
expression in HCC by applying a competing risk approach.
Materials and methods
Patients and tissue samples. HCC tumor samples, matched 
adjacent non-tumor hepatic tissues and clinical data from 
156 patients who underwent curative surgical resection 
between 1989 and 2009 were obtained from the Department 
of Pathology, National University Hospital of Singapore 
(NUH). This study was approved by the National University 
of Singapore (NUS)-Institutional Review Board (IRB 09-112).
Tissue microarray and immunohistochemistry. The tissues 
were deparaffinized and rehydrated before antigen retrieval 
was performed by heating the sections for 30 min in antigen 
unmasking solution (Vector Laboratories Inc., Burlingame, 
CA, USA) using the microwave oven. The sections were then 
treated with 3% hydrogen peroxide, washed in phosphate-buff-
ered saline with Tween-20 (PBST) (1X PBS, 0.1% Tween-20), 
and incubated with primary antibodies overnight at 4˚C. 
Rabbit polyclonal antibody against HDAC1 from Abcam 
Inc. (Cambridge, MA, USA) was used at a 1:8,000 dilution, 
while rabbit polyclonal antibody against HDAC2 from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) was used at 
a 1:200 dilution. Sections were then washed and incubated 
with a goat anti-rabbit IgG conjugated with avidin-biotinylated 
horseradish peroxidase (Dako, Glostrup, Denmark), before 
final washing and incubation for 1 min with DAB substrate. 
Counterstaining was conducted using hematoxylin solution 
(Sigma-Aldrich, St. Louis, MO, USA).
Scoring of the tissue microarray. Each sample on the tissue 
microarray slides was scored based on the intensity of HDAC 
staining in the nuclei of the hepatocytes, as the presence of 
nuclear HDACs is relevant to their transcription-modifying 
activities. A score of 0 indicated no staining while a score 
of 1, 2 and 3 represented low, moderate and intense staining 
respectively.
Statistical analysis. The deceased and living status of patients 
was determined using the in-house hospital database as well 
as the registry of births and deaths, while the recurrence 
status was determined using the in-house hospital database. 
Results are expressed as mean ± SD for continuous variables 
or percentages for dichotomous variables.
As for descriptive statistics, overall frequencies and distri-
bution of demographic and clinicopathological parameters 
by HDAC1 and HDAC2 expression status were calculated by 
either 2 by 2 or 2 by K tables with Chi-squared test and Fisher's 
exact test with the frequency weights (fweights) option to take 
into account duplicated observations of tumors and adjacent 
non-tumor. And two sample mean comparison test between 
biomarkers positive and negative statuses were made using 
ANCOVA test with the frequency weights (fweights) option 
to take into account duplicated observations of tumors and 
adjacent non-tumor. The comparisons between HDAC1 and 
HDAC2 expression status between tumor and non-tumor tissue 
were made using McNemar test. The presence of HDAC1 
expression in tumor and non-tumor tissue was identified using 
the cut-off score value of ≥1, and no expression of HDAC1 in 
tumor and non-tumor score was identified using ‘0’ and treated 
as a reference group. In addition, the levels of HDAC1 expres-
sion in tumor and non-tumor tissue were identified as low level 
of expression with a score cut-off 0 to 1 point, and identified as 
high level of expression with a score cut-off >2 points in tumor 
and non-tumor tissues. Similar comparisons were applied to 
the HDAC2 gene expression.
Associations of HDAC1 and HDAC2 gene expression 
with disease-specific mortality and recurrence were assessed 
using standard univariate and multivariate Cox proportional 
hazard model with robust standard error estimates to allow 
for intragroup correlation for tumor and adjacent non-tumor 
tissue measurements in the same patient. Kaplan-Meier's 
survival curves with log-rank tests for comparisons of survival 
curves were also constructed. The duration of follow-up in this 
study was 10 years with median survival time of 6.96 (95% CI, 
4.85-7.46).
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Standard Cox proportional hazards model, which 
assumes that the hazard ratio is constant over time, was 
applied initially. The proportionality assumption of the Cox 
regression model was assessed graphically and with the use 
of Schoenfeld residuals (21-22) using ‘estat phtest’ STATA 
command after fitting a model with stcox. However, violations 
of the Cox proportional hazards assumption were observed 
for both HDAC1 and HDAC2 gene expression in tumor and 
non-tumor tissue to predict mortality and disease-free survival 
(DFS), as discussed in the Results section below. Hence, the 
competing risk regression model was used to estimate the 
impact of HDAC1 and HDAC2 expression (as main covari-
ates of interest) on the probability of mortality due to HCC, 
in which disease recurrence was treated as a competing event. 
Similarly, death due to HCC was treated as a competing event 
when estimating the impact of HDAC1 and HDAC2 expres-
sion on the probability of recurrence due to HCC. The results 
(effect sizes) are expressed as sub-hazard ratios (SHR). In 
Figure 1. Overall cumulative mortality rate among patients with HCC. 
Duration of follow-up was 10 years; median survival time was 6.96 (95% CI, 
4.85-7.46). HCC, hepatocellular carcinoma.
Figure 2. Immunohistochemical analysis of the hepatocellular carcinoma tissue microarray. (A) Representative examples of scoring performed for HDAC1 
staining on tumor tissue. A tissue section with negative staining was given a score of 0 while scores 1-3 indicate the intensity of the nuclear staining of the 
hepatocytes. (B) Representative examples of scoring performed for HDAC2 staining on tumor tissue. A tissue section with negative staining was given a score 
of 0 while scores 1-3 indicate the intensity of nuclear staining of the hepatocytes. Scale bar, 50 µm. HDAC, histone deacetylase.
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Table I. Overall frequencies and distribution of demographic 
and clinicopathological parameters by HDAC1 and HDAC2 
expression status.
A, HDAC1 status and patient parameters
Variables HDAC1(-) HDAC1(+) P-value
Age, mean (± SD) 57.81 (±13.02) 58.27 (±13.24) 0.8219
Gender, n (%)
  Female   4 (10.81) 26 (21.85) 0.137
  Male 33 (89.19) 93 (78.15)
Race, n (%)
  Non-Chinese 29 (78.38) 90 (76.27) 0.791
  Chinese   8 (21.62) 28 (23.73)
Smoking, n (%)
  Non-smoker 21 (58.33) 60 (61.86) 0.711
  Smoker 15 (41.67) 37 (38.14)
Alcohol, n (%)
  Non-drinker 21 (58.33) 62 (60.78) 0.796
  Drinker 15 (41.67) 40 (39.22)
HBV status, n (%)
  Non-carrier 13 (36.11) 41 (35.04) 0.907
  Carrier 23 (63.89) 76 (64.96)
HCV status, n (%)
  Non-carrier 34 (91.89) 112 (94.92) 0.493
  Carrier 3 (8.11)  6 (5.08)
Liver capsule, n (%)
  Absence 0 3 (4.55) 0.570
  Presence 22 (100) 63 (95.45)
Satellite nodules, n (%)
  Absence    35 (94.59) 104 (87.39) 0.364
  Presence    2 (5.41)   15 (12.61)
Multiple lesions, n (%)
  No    29 (78.38) 104 (87.39) 0.177
  Yes      8 (21.62)   15 (12.61)
Histological grade, n (%)
(differentiation)
  Well    13 (38.24)  18 (17.14) 0.028
  Moderate    16 (47.06)  73 (69.52)
  Poor      5 (14.71)  14 (13.33)
Lymphatic invasion, n (%)
   No     11 (91.67)  57 (85.07) 1.000
  Yes     1 (8.33)  10 (14.93)
Vascular invasion, n (%)
  No    19 (65.52)  67 (64.42) 0.913
  Yes    10 (34.48)  37 (35.58)
Cirrhosis, n (%)
  No   16 (43.24)  63 (52.94) 0.303
  Yes   21 (56.76)  56 (47.06)
Tumor stage, n (%)
  Stage 1  16 (44.44)  60 (50.42) 0.559
  Stage 2  14 (38.89)  35 (29.41)
  Stage 3 and above    6 (16.67)  24 (20.17)
AFP 1,544.24 3,149.28 0.5184
 (±9,235.63) (±5,784.32) 
CEA 3.60 (±2.88) 2.75 (±2.54) 0.2939
B, HDAC2 status and patient parameters
Variables HDAC2(-) HDAC2(+) P-value
Age, mean (± SD) 56.09 (±13.53) 58.69 (±12.97) 0.961
Gender, n (%)
  Female 1 (10)   29 (19.86) 0.688
  Male 9 (90) 117 (80.14)
Race, n (%)
  Non-Chinese 8 (80) 111 (76.55) 1.000
  Chinese 2 (20)  34 (23.45)
Smoking, n (%)
  Non-smoker 6 (60)   75 (60.98) 1.000
  Smoker 4 (40)   48 (39.02)
Alcohol, n (%)
  Non-drinker 7 (70)   76 (59.38) 0.740
  Drinker 3 (30)   52 (40.63)
HBV status, n (%)
  Non-carrier 1 (10)   53 (37.06) 0.099
  Carrier 9 (90)   90 (62.94)
HCV status, n (%)
  Non-carrier 10 (100) 136 (93.79) 1.000
  Carrier 0   9 (6.21)
Liver capsule, n (%)
  Absence      1 (33.33)   2 (2.35) 0.100
  Presence      2 (66.67)   83 (97.65)
Satellite nodules, n (%)
  Absence 10 (100) 129 (88.36) 0.602
  Presence 0   17 (11.64)
Multiple lesions, n (%)
  No 8 (80) 125 (85.62) 0.643
  Yes 2 (20)   21 (14.38)
Histological grade, n (%)
 (differentiation)
  Well      3 (33.33)   28 (21.54) 0.222
  Moderate      6 (66.67)   83 (63.85)
  Poor 0   19 (14.62)
Lymphatic invasion,n (%)
  No   2 (100)   66 (85.71) 1.000
  Yes 0   11 (14.29)
Vascular invasion, n (%)
  No     4 (57.14)   82 (65.08)
  Yes     3 (42.86)   44 (34.92)
Cirrhosis, n (%)
  No 3 (30)   76 (52.05) 0.207
  Yes 7 (70)   70 (47.95)
Tumor stage, n (%)
  Stage 1 4 (40)   72 (49.66) 0.416
  Stage 2 5 (50)   44 (30.34)
  Stage 3 and above 1 (10) 29 (20)
AFP 1,372.45 2,862 0.4536
 (±2,933.55) (±9,098.68)
CEA 2.03 (±1.24) 3.42 (±3.44) 0.4292
HDAC, histone deacetylase.
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addition, we adjusted for various demographic, clinicopatho-
logical factors, including tumor staging. The crude cumulative 
probability of mortality while accounting for the dependence 
of the cumulative probability function (CPF) on the hazards of 
other competing event (i.e., disease recurrence) was calculated. 
We then compared the resulting curves between two groups 
based on the absence vs. presence of HDAC2 expression in 
tumor and non-tumor tissue. With the same approach, we also 
compared the resulting curves between two groups based on 
low expression (score of 0-1) vs. high expression (score of ≥2) 
of HDAC1 in tumor and non-tumor tissue.
All statistical analyses were performed using Stata statis-
tical software (version 11.1; StataCorp LP, College Station, 
TX, uSA).
Cell lines. The human colon cancer cell line, HCT116, and 
human hepatocarcinoma cell lines, HEP3B, HEPG2 and 
PLC5, were purchased from the American Type Culture 
Collection (ATCC; Rockville, MD, USA). The HCT116 
cells were cultured in McCoy's 5A (Sigma-Aldrich) medium 
supplemented with 10% fetal bovine serum (Gibco, Grand 
Island, NY, uSA). The HEP3B, HEPG2 and PLC5 cells were 
cultured in Dulbecco's modified Eagle's medium (DMEM; 
Sigma-Aldrich) supplemented with 10% fetal bovine serum 
(Gibco). The cells were maintained in an incubator at 37˚C in 
a 5% CO2 humidified atmosphere.
Transfection. Twenty-four hours before transfection, the cells 
were counted and plated. Twenty picomoles of Invitrogen's 
Stealth Select siRNA (a pool of three different sequences 
targeting the same gene) or universal control siRNA with 
matching percentage GC content and Lipofectamine 
RNAiMax reagent (Invitrogen) was used according to the 
manufacturer's instructions. The siRNA sequences along the 
HDAC1 mRNA sequence (5'-3') were: aacgaauugccugugaggaa 
gaguu (siRNA 1A), gcaugacucauaauuugcugcucaa (siRNA 1B), 
and caguauucgauggccuguuugaguuc (siRNA 1C). The siRNA 
sequences along the HDAC2 mRNA sequence (5'-3') were: ucu 
aacagucaaaggucaugcuaaa (siRNA 2A), gaagauccagacaagagaa 
uuucua (siRNA 2B), and ggugauggagauguaucaaccuagu 
(siRNA 2C).
Cell cycle analysis. Cells were washed in 1X PBS, trypsinized, 
and collected. Both the live adherent and dead floating cells 
were collected and pelleted at 2,500 rpm for 5 min at 4˚C. 
They were washed in 1X PBS, fixed in cold 70% ethanol and 
stored in -20˚C for overnight. The fixed cells were centrifuged 
at 2,500 rpm for 5 min at 4˚C and washed once in 1X PBS. 
They were then resuspended in 500 µl propidium iodide (PI) 
staining solution (0.1% Triton X-100, 0.2 mg/ml RNaseA, 
0.02 mg/ml PI, in 1X PBS) and incubated for 15 min at 37˚C 
in the dark. The PI-stained cells were filtered through a 40-µm 
filter before passing through a Beckman Coulter Epics Altra at 
the Flow Cytometry unit at the National university Medical 
Institute. Ten thousand cells were analyzed for each sample to 
generate a cell cycle profile. Analysis was carried out using 
WinMDI software.
WST-1 cell proliferation assay. To measure cell proliferation, 
the colorimetric assay was performed using WST-1 reagent 
(Roche Applied Science, Indianapolis, IN, uSA). Twelve 
hours post-transfection, the cells were trypsinized, counted 
and replated at 500 cells/well in a 96-well plate. Twenty-four 
hours after replating, 10 µl of WST-1 reagent was added to 
each well containing 100 µl of media. The plate was returned 
Figure 3. Immunohistochemical analysis of the hepatocellular carcinoma tissue microarray. (A) A representative example of scoring for HDAC1 staining on 
matched adjacent non-tumor tissue. (B) A representative example of scoring for HDAC2 staining on matched adjacent non-tumor tissue. Scale bar, 50 µm. 
HDAC, histone deacetylase.
Table II. Distribution of biomarkers according to tumor and 
adjacent non-tumor tissues.
Variables HDAC1 P-value HDAC2 P-value
Overall, n (%)
  No 139 (44.55) 0.0791 69 (22.12) <0.001
  Yes 173 (55.45)  243 (77.88)
Expression status
  (+) in T 119 (76.28) <0.0001 146 (93.59) <0.0001
  (+) in NT 54 (34.62)  97 (62.18)
Scores in T
  0-1 88 (56.41) <0.0001 60 (38.46) <0.008
  ≥2 68 (43.59)  96 (61.54)
Scores in NT
  0-1 142 (91.03)  136 (87.18)
  ≥2 14 (8.97)  20 (12.82)
T, tumor tissues; NT, non-tumor tissues; HDAC, histone deacetylase.
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Table III. Adjusted hazard ratio estimates and SHR estimates of HDAC1 and HDAC2 gene expression in the prediction of cancer-
specific mortality among patients with HCC by final fitted Cox proportional hazard model and final fitted competing risk model.
 Multivariate Cox regression Multivariate competing risk regression
 (final fitted model) (final fitted model)
 ----------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
Variables Adjusted HR 95% CI P-value Adjusted SHR 95% CI P-value
Tumor stage
  Stage I 1.0 - - - - -
  Stage II 2.15 0.83-5.60 0.117 0.52 0.14-1.91 0.328
  Stage ≥III 5.67 1.77-18.13 0.003 0.37 0.04-3.45 0.379
Cirrhosis 
  Absence 1.0 - - 1.0 - -
  Presence 2.05 1.10-3.79 0.023 3.84 1.14-13.01 0.030
Multiple lesions
  Absence  1.0 - - 1.0 - -
  Presence  0.74 0.23-2.37 0.615 2.00 0.30-13.46 0.478
Vascular invasion
  Absence  1.0 - - 1.0 - -
  Presence  1.69 0.72-3.95 0.227 1.83 0.47-7.08 0.380
Age at diagnosis 1.01 0.99-1.04 0.282 1.03 0.98-1.07 0.220
HDAC1 gene expression status
  HDAC1(-) (T and NT)  1.0 - - 1.0 - -
  HDAC1(+) (NT) 1.25 0.66-2.34 0.490 1.65 0.44-6.16 0.453
  HDAC1(+) (T) 1.23 0.60-2.52 0.570 0.52 0.12-2.27 0.382
HDAC2 gene expression status 
  HDAC2(-) (T and NT)  1.0 - - 1.0 - -
  HDAC2(+) (NT) 1.77 0.83-3.79 0.141 6.04 0.66-55.57 0.112
  HDAC2(+) (T) 1.43 0.63-3.23 0.393 9.24 1.76-48.43 0.009
T, tumor tissues; NT, non-tumor tissues; SHR, sub-hazard ratio; HDAC, histone deacetylase; HCC, hepatocellular carcinoma.
Figure 4. Cancer-specific mortality based on HDAC expression. (A) The cumulative incidence for cancer-specific mortality comparing the presence and 
absence of HDAC2 (H2) gene expression in tumor and non-tumor tissues based on the competing risks regression model. (B) The cumulative incidence for 
cancer-specific mortality comparing levels of HDAC1 (H1) gene expression in tumor and non-tumor tissues based on the competing risks regression model. T, 
tumor tissues; NT, non-tumor tissues; HDAC, histone deacetylase.
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to the incubator for 4 h before the absorbance was read at 
460 nm using a spectrophotometer. A ‘blank’ well with only 
the media and WST-1 reagent but without cells was used as 
negative control.
Colony formation assay. Between 24 to 48 h after transfection 
or drug treatment, cells were harvested, counted and plated 
in triplicate at 1,000 cells/well in a 6-well plate. After 10 to 
14 days, the wells were washed in 1X PBS and the colonies 
were stained with crystal violet solution. The plates were 
then scanned and the images were analyzed using the ImageJ 
(NIH) software to measure the number of colonies formed in 
each well.
Results
Expression of HDAC1 and HDAC2 in HCC tissues 
and correlation with clinicopathological parameters. 
Immunohistochemistry was performed on a tissue micro-
array constructed from 156 pairs of HCC tissues and their 
matched adjacent non-tumor tissues to examine the expression 
of HDAC1 and HDAC2. Scoring was based on the HDAC 
staining intensity of the hepatocyte nuclei, where HDACs are 
known to function, with 0 being undetectable and 3 being the 
most intensely stained. An IgG-isotype antibody was used as 
the negative control. The overall cumulative mortality rate of 
patients is shown in Fig. 1. The scoring intensities for HDAC1 
and HDAC2 in tumor tissues are shown in Fig. 2, respectively, 
and the scoring intensities for the respective non-tumor tissues 
are shown in Fig. 3. The overall frequencies and distribu-
tion of demographic and clinicopathological parameters by 
status of HDAC1 and HDAC2 expression status are shown in 
Table 1A and B.
Overall, we observed that the levels of both HDAC1 and 
HDAC2 in tumor tissues were significantly higher than those 
noted in adjacent non-tumor tissues (P<0.0001, Table II). In 
addition, the levels of HDAC1 and HDAC2 expression (i.e., 
expression level ≥2) were significantly high in the tumor 
tissues when compared to the adjacent non-tumor tissues 
(P<0.0001 for both HDAC1 and HDAC2 by McNemar test) 
(Table II). HDAC1 expression in tumor tissues (but not 
HDAC2) was higher in the moderately and poorly differ-
entiated tumors compared to that in the well-differentiated 
tumors (P=0.028).
Table IV. Adjusted hazard ratio estimates and SHR estimates of the HDAC1 and HDAC2 genes with high level expression in the 
prediction of cancer-specific mortality among patients with HCC by final fitted Cox proportional hazard model and final fitted 
competing risk model.
 Multivariate Cox regression Multivariate competing risk regression
 (final fitted model) (final fitted model)
 ------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------
Variables Adjusted HR 95% CI P-value Adjusted SHR 95% CI P-value
Tumor stage
  Stage I 1.00 - - 1.00 - -
  Stage II 1.83 0.76-4.40 0.174 0.61 0.16-2.32 0.467
  Stage ≥III 5.85 2.04-16.77 0.001 0.54 0.08-3.70 0.531
Cirrhosis
  Absence 1.00 - - 1.00 - -
  Presence 1.99 1.09-3.65 0.025 3.46 1.10-10.81 0.033
Multiple lesions
  Absence 1.00 - - 1.00 - -
  Presence 0.86 0.32-2.35 0.772 2.31 0.41-12.89 0.339
Vascular invasion
  Absence 1.00 - - 1.00 - -
  Presence 1.55 0.73-3.28 0.256 1.38 0.43-4.43 0.588
Age at diagnosis 1.02 0.99-1.04 0.167 1.03 0.98-1.08 0.223
HDAC1 gene expression
  HDAC1 score 0-1 (T and NT)  1.00 - - 1.00 - -
  HDAC1 score ≥2  (NT) 0.97 0.27-3.45 0.964 1.08 0.07-17.64 0.959
  HDAC1 score ≥2 (T) 1.62 0.92-2.85 0.092 2.48 0.88-7.00 0.085
HDAC2 gene expression
  HDAC2 score 0-1 (T and NT)  1.00 - - 1.00 - -
  HDAC2 score ≥2 in NT 0.10 0.01-0.97 0.047 0.75 0.04-14.70 0.850
  HDAC2 score ≥2 in T 0.76 0.48-1.22 0.261 0.65 0.23-1.82 0.411
T, tumor tissues; NT, non-tumor tissues; SHR, sub-hazard ratio; HDAC, histone deacetylase; HCC, hepatocellular carcinoma.
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Prognostic value of HDAC1 and HDAC2 and competing risk 
regression model. The competing risk regression method was 
used to estimate the impact of HDAC1 and HDAC2 expression 
(as main covariates of interest) on mortality and disease recur-
rence. The final fitted competing risk regression model showed 
that the presence of HDAC2 expression (score ≥1) in tumor 
tissues is a significant independent predictor of mortality 
after adjusting for other significant risk factors while taking 
into account disease recurrence as the other competing risk 
event (Table III and Fig. 4A). The final adjusted SHR estimate 
was 9.24 (95% CI, 1.76-48.43; P=0.009) (Table III). The final 
adjusted SHR in the final competing risk model was adjusted 
for other clinically important and statistically significant vari-
ables in the univariate testing. These adjusting variables were 
age at diagnosis, tumor stage, presence of cirrhosis, presence 
of multiple lesions, the presence of vascular invasion, and pres-
ence of HDAC1 expression in tumor and non-tumor tissues.
The prediction of mortality by levels of HDAC1 expression 
(i.e., score 0-1 vs. ≥2) as a main covariate of interest showed a 
tendency towards higher risk of mortality in patients with high 
HDAC1 expression in tumors (Table IV and Fig. 4B), although 
the presence of HDAC1 expression alone was not found to 
be a significant predictor of mortality. The SHR estimate for 
high HDAC1 expression levels (score ≥2) in the tumor tissues 
was 2.48 with 95% CI, 0.88-7.00. However, this value did not 
reach statistically significant levels. As for the prediction of 
disease recurrence using multivariate competing risk regres-
sion approach, neither the presence of HDAC1 or HDAC2 (i.e., 
score ≥1), nor the levels of HDAC1 or HDAC2 expression (i.e., 
score 0-1 vs. score ≥2) prognosticated HCC recurrences in our 
population (Tables V and VI).
There was no significant interaction between HDAC1 
and HDAC2 in prediction of both cancer recurrence and 
cancer-specific mortality in this study when HDAC1 and 
HDAC2 were treated as either presence or absence categories 
or different levels of expression in the competing risk model.
Combined knockdown of HDAC1 and HDAC2 increases 
cell death and reduces cell proliferation and colony forma-
tion. The expression of HDAC1 and HDAC2 was knocked 
down by siRNAs both individually and in combination 
in three liver cancer cell lines, HEP3B (Fig. 5A and B), 
HEPG2 (Fig. 6A), PLC5 (Fig. 6C) and a colorectal cancer cell 
line, HCT116 (Fig. 6E). To investigate the effects of HDAC1 
and HDAC2 on cell proliferation, WST-1 assay was performed 
on HEP3B cells treated with HDAC1 and HDAC2 siRNAs in 
Table V. Adjusted hazard ratio estimates and SHR estimates of HDAC1 and HDAC2 gene expression in the predictions of 
recurrence of HCC among patients with HCC by final fitted Cox proportional hazard model and final fitted competing risk model.
 Multivariate Cox regression Multivariate competing risk regression
 (final fitted model) (final fitted model)
 -------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
Variables Adjusted HR 95% CI P-value Adjusted SHR 95% CI P-value
Tumor stage
  Stage I 1.0 - - 1.0 - -
  Stage II 0.69 0.28-1.68 0.413 1.59 0.85-2.98 0.146
  Stage ≥III 1.12 0.40-3.17 0.828 2.98 1.34-6.61 0.007
Cirrhosis
  Absence 1.0 - - 1.0 - -
  Presence 1.40 0.83-2.34 0.203 0.97 0.62-1.51 0.897
Multiple lesions
  Absence  1.0 - - 1.0 - -
  Presence  2.79 0.80-9.78 0.109 0.64 0.24-1.73 0.378
Vascular invasion
  Absence  1.0 - - 1.0 - -
  Presence  3.03 1.40-6.59 0.005 1.48 0.81-2.70 0.206
Age at diagnosis  0.98 0.96-1.00 0.024 1.01 0.99-1.02 0.305
HDAC1 gene expression
  HDAC1 score 0-1 (T and NT) 1.0 - - 1.0 - -
  HDAC1 score ≥2  (NT) 1.35 0.75-2.42 0.323 0.98 0.60-1.59 0.921
  HDAC1 score ≥2 (T) 1.35 0.76-2.37 0.302 1.24 0.74-2.08 0.404
HDAC2 gene expression
  HDAC2 score 0-1 (T and NT) 1.0 - - 1.0 - -
  HDAC2 score ≥2 (NT) 1.21 0.67-2.20 0.529 1.37 0.87-2.17 0.179
  HDAC2 score ≥2  (T) 0.94 0.51-1.76 0.854 1.05 0.61-1.79 0.858
T, tumor tissues; NT, non-tumor tissues; SHR, sub-hazard ratio; HDAC, histone deacetylase; HCC, hepatocellular carcinoma.
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combination or individually, and compared with scrambled 
siRNA-treated (Scr) and untransfected control cells (Ctrl). 
Silencing of both HDAC1 and HDAC2 in HEP3B cells signifi-
cantly reduced cell growth compared to the controls. However, 
knockdown of either HDAC1 or HDAC2 alone did not affect 
cell proliferation (Fig. 5C). In addition, colony formation was 
reduced when both HDAC1 and HDAC2 were knocked down 
in HEP3B cells, but not when HDAC1 and HDAC2 were 
silenced individually (Fig. 5D). Similarly, significant reduc-
tion in colony formation was only observed when combined 
knockdown of HDAC1 and HDAC2 was performed in the 
HEPG2 (Fig. 6B), PLC5 (Fig. 6D) and HCT116 (Fig. 6F) cell 
lines.
The effects of HDAC1 and HDAC2 on cell death was 
assessed by PI staining of fixed HEP3B cells treated with 
HDAC1 and HDAC2 siRNAs and control siRNA as above. 
Flow cytometric analysis showed that combined knockdown of 
both HDAC1 and HDAC2 significantly increased the sub-G1 
fraction by 22.5% at 96 h post-transfection, compared to ~2% 
in the scrambled siRNA and untreated controls, indicating 
increased cell death (Fig. 7A and B). In contrast, knockdown of 
either HDAC1 or HDAC2 alone did not significantly affect cell 
death. The expression of various proteins involved in apoptosis 
was investigated by western blotting (Fig. 7C). Consistent 
with the flow cytometric data on cell death, cleavage of 
caspase-3 as well as its substrate PARP were observed in cells 
in which both HDAC1 and HDAC2 were knocked down up 
to 120 h post-transfection, but not in cells treated with either 
HDAC1 or HDAC2 siRNA. Taken together, our data suggest 
that the combined targeting of HDAC1 and HDAC2 in hepa-
tocellular and colon cancer cells is more effective in reducing 
their growth potential and inducing cell death than selective 
targeting of either HDAC.
Discussion
In the Singapore cohort of 156 patients, we found that the expres-
sion levels of HDAC1 and HDAC2 in the tumor tissues were 
significantly higher than those in matched adjacent non-tumor 
tissues, as reported in other studies (13,23-25). HDAC1 expres-
sion was also higher in moderately and poorly differentiated 
tumors compared to well-differentiated tumors. Our data are 
consistent with previous observations whereby high tumor 
HDAC1 was found to be associated with poorer differentiation 
Table VI. Adjusted hazard ratio estimates and SHR estimates of HDAC1 and HDAC2 genes with high-level expression in 
the predictions of recurrence of HCC among patients with HCC by final fitted Cox proportional hazard model and final fitted 
competing risk model.
 Multivariate Cox regression Multivariate competing risk regression
 (final fitted model) (final fitted model)
 --------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
Variables Adjusted HR 95% CI P-value Adjusted SHR 95% CI P-value
Tumor stage
  Stage I 1.00 - - 1.00 - -
  Stage II 0.73 0.30-1.78 0.483 1.58 0.84-2.96 0.156
  Stage ≥III 1.17 0.42-3.27 0.762 3.09 1.39-6.87 0.006
Cirrhosis
  Absence 1.00 - - 1.00 - -
  Presence 1.41 0.84-2.36 0.194 0.97 0.62-1.50 0.875
Multiple lesion
  Absence 1.00 - - 1.00 - -
  Presence 2.88 0.84-9.91 0.093 0.65 0.24-1.73 0.382
Vascular invasion
  Absence 1.00 - - 1.00 - -
  Presence  2.71 1.23-5.93 0.013 1.45 0.79-2.64 0.231
Age at diagnosis 0.98 0.96-1.00 0.060 1.01 0.99-1.03 0.277
HDAC1 gene expression
  HDAC1 score 0-1 (T and NT)  1.00 - - 1.00 - -
  HDAC1 score ≥2 (NT) 0.77 0.43-1.41 0.401 0.86 0.45-1.64 0.652
  HDAC1 score ≥2 (T) 1.02 0.61-1.69 0.944 0.92 0.60-1.41 0.696
HDAC2 gene expression
  HDAC2 score 0-1 (T and NT)  1.00 - - 1.00 - -
  HDAC2 score ≥2 (NT) 0.71 0.43-1.18 0.185 1.01 0.56-1.82 0.982
  HDAC2 score ≥2 (T) 0.87 0.58-1.32 0.516 0.96 0.69-1.33 0.795
T, tumor tissues; NT, non-tumor tissues; SHR, sub-hazard ratio; HDAC, histone deacetylase; HCC, hepatocellular carcinoma.
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and invasion into the portal vein (26). Multivariate analysis 
using the competing risk regression model was performed 
for our cohort. The standard Cox proportional hazard model 
was not used as it found to be inappropriate for our analysis 
- violation of the Cox proportional hazards assumption was 
noted when we applied the presence or absence of HDAC1 
and HDAC2 gene expression in tumor and non-tumor tissues 
to predict mortality and DFS (Fig. 8A). A similar violation 
was found when we applied the high and low level of HDAC1 
and HDAC2 gene expression (i.e., 0-1 vs. ≥2) in tumor and 
non-tumor tissues to predict mortality and DFS (Fig. 8B). The 
competing risk regression model revealed that high expression 
of HDAC1 in tumor tissues (score ≥2) independently predicted 
cancer-specific mortality. Our findings are consistent with 
Rikimaru et al, who showed that high HDAC1 expression was 
associated with poorer survival in HCC patients after hepatic 
resection (26).
Recent evidence suggests that HDAC2 promotes malig-
nant progression in HCC by activating Akt signaling and 
epithelial-mesenchymal transformation (23). Consistent with 
Figure 5. Effects of siRNA knockdown of HDAC1 and/or HDAC2 on HDAC activity in HEP3B cells. Cells were transfected with HDAC1 siRNA (H1), or 
HDAC2 siRNA (H2), or both (H1+2), or non-silencing control siRNA (Scr) for 72 h. (A) Cells were harvested and RNA was extracted and used for quantitative 
real time RT-PCR, carried out in replicates. The sequences specific for HDAC1 (1A and 1B) resulted in reduced RNA expression of HDAC1 compared to the 
non-silencing control (Scr) but not HDAC2, and the sequences specific for HDAC2 (2A, 2B, and 2C) resulted in reduced RNA expression of HDAC2 compared 
to the non-silencing control (Scr) but not HDAC1. (B) Cells transfected with a cocktail of HDAC1 siRNAs and/or HDAC2 siRNAs were harvested for protein, 
and western blot analysis using HDAC1- and HDAC2-specific antibodies was performed. GAPDH was used as the loading control. (C) WST-1 assay showed 
that combined knockdown of HDAC1 and HDAC2 reduced the cell growth over time. HEP3B cells were transfected with HDAC1 siRNA (H1), or HDAC2 
siRNA (H2), or both (H1+2), or non-silencing control siRNA (Scr) or untransfected (Ctrl). (D) Left panel: Quantification of colony formation. The average 
number of colonies in each of the triplicate wells was plotted against the treatment. Error bars indicate standard deviations. Right panel: Representative images 
of the crystal violet-stained colonies. The combined knockdown of both HDAC1 and HDAC2 reduced colony formation. Cells were plated at a low density for 
10 days and colonies were stained with crystal violet before imaging. HDAC, histone deacetylase.
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the roles of HDAC2 in cancer progression, we found that 
the presence of HDAC2 in tumor tissues (score ≥1) was an 
independent predictor of cancer-specific mortality. This is in 
agreement with other studies which demonstrate a correlation 
between high HDAC2 expression and shorter overall survival 
in several cancers including HCC (23,24), oral cancer (27), 
gastric cancer (28) and colorectal cancer (14). In addition, 
HDAC2 presence in adjacent non-tumor hepatic tissues was 
also identified by the competing risk regression model as a 
potential predictor of poorer survival, although this did not 
reach levels of significance (P=0.112).
Importantly, we also found a significant correlation 
between HDAC1 expression in adjacent non-tumor hepatic 
tissues with the presence of satellite nodules and multiple 
lesions, suggesting that HDAC1 activation in the adjacent 
tumor environment may contribute to tumor spread. With 
respect to HDAC2, its presence in adjacent non-tumor hepatic 
tissues was significantly associated with smoking. Previous 
observations have implicated smoking as a risk factor in the 
development of HCC (29), while HDAC inhibition was shown 
to reduce the risk of smoking-related cancers such as head and 
neck cancers (30). It is thus possible that HDAC2 upregulation 
occurs as an early event in smoking-related hepatocellular 
transformation.
Our in vitro studies showed that combined knockdown 
of HDAC1 and HDAC2 (but not knockdown of either alone) 
reduced cell proliferation and survival in HCC and colon cancer 
cell lines. The requirement for both HDAC1 and HDAC2 for 
cell proliferation was previously observed in B-cell develop-
ment, whereby HDAC1 and HDAC2 act together to promote 
G1 to S phase progression by inhibiting the transcription of 
cyclin-dependent kinase inhibitors p21WAF1/CIP1 and p57Kip2 (31). 
In HCC, HDAC2 was shown to be important for oncogenic 
potential and inhibits the transcription of p21WAF1/Cip1 by 
binding to Sp1-binding site enriched proximal region of the 
p21WAF1/Cip1 promoter (32). In addition, a positive feedback 
mechanism that upregulates HDAC2 expression in response 
to growth factors via the PI3 kinase/mTORC1/NF-κBp50 
signaling was also identified in HCC cells (23). In these cells, 
increased HDAC2 activity in turn was found to be required 
Figure 6. HDAC1 and/or HDAC2 knockdown. Western blot analysis shows the knockdown of protein expression of HDAC1 and/or HDAC2 in (A) HEPG2, 
(C) PLC5 and (E) HCT116 cells. Cells were transfected with HDAC1 siRNA (H1) or HDAC2 siRNA (H2), or both (H1+2), or non-silencing control siRNA 
(Scr). After 72 h, cells were harvested for protein, and western blot analysis using HDAC1- and HDAC2-specific antibodies was carried out. GAPDH was used 
as a loading control. Quantification of colony formation in (B) HEPG2, (D) PLC5 and (F) HCT116 after HDAC1 and/or HDAC2 were knocked down in the 
cells. The average number of colonies in each of the triplicate wells was plotted against the treatment. Error bars showed standard deviations. The knockdown 
of both HDAC1 and HDAC2 together was required to reduce colony formation. HDAC, histone deacetylase.
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Figure 7. Analysis of cell death in HEP3B cells after treatment with HDAC1 and/or HDAC2 siRNA. (A) Cell cycle analysis at 96 h after siRNA treatment. 
The combined knockdown of both HDAC1 and HDAC2 increased the percentage of cells in the subG1 and reduced the percentage of cells in the G1 phase of 
the cell cycle, indicating increased cell death. Representative flow diagrams of PI-stained cells are shown. (B) The percentages of cells in each phase of the 
cell cycle were quantified at 96 h after siRNA treatment. The graph shown is representative of at least three experiments. (C) Increase in apoptotic proteins 
after HDAC1 and HDAC2 knockdown. Expression of apoptotic proteins in HEP3B was detected by western blot analysis at 96 and 120 h after transfection 
with siRNA against HDAC1 (H1) or HDAC2 (H2) or both (1+2) or non-silencing control (Scr) or untransfected control (ctrl). There was cleavage of caspase-3 
(as indicated by the white arrow) as well as PARP (as indicated by the red arrow). β-actin was used as the loading control. HDAC, histone deacetylase; PI, 
propidium iodide.
Figure 8. Kaplan-Meier cumulative incidence estimates of mortality by HDAC expression. (A) Comparison of Kaplan-Meier cumulative incidence estimates of 
mortality by HDAC2 (H2) expression status in tumor and non-tumor tissues via log-rank test. (B) Comparison of Kaplan-Meier cumulative incidence estimates 
of mortality by levels of HDAC1 (H1) expression in tumor and non-tumor tissues via log-rank test. T, tumor tissues; NT, non-tumor tissues; HDAC, histone 
deacetylase.
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for sustaining elevated PI3 kinase/Akt and mTOR signaling 
to promote cancer cell growth and survival (23). Notably, 
both HDAC1 and HDAC2 have been found together in asso-
ciation with transcriptional complexes that regulate oncogenic 
processes, such as the ZEB1/HDAC transcription complex 
which represses E-cadherin expression and promotes migra-
tion of pancreatic cancer cells (33). Our clinical and in vitro 
data suggest that HDAC1 and HDAC2 also have independent 
functions that contribute to cancer progression, hence targeting 
both HDACs could be a useful therapeutic consideration to 
reduce cancer spread and improve the mortality rate.
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